tbuckley/cabot-search huggingface dataset:
Employment Changes Following Breast Cancer Diagnosis: The Effects of Race and Place
Authors: Jennifer C Spencer, Jason S Rotter, Jan M Eberth, Whitney E Zahnd, Robin C Vanderpool, Linda K Ko, Melinda M Davis, Melissa A Troester, Andrew F Olshan, Stephanie B Wheeler
Journal: JNCI Journal of the National Cancer Institute (2019)

The financial implications of breast cancer diagnosis may be greater among rural and black women. Women with incident breast cancer were recruited as part of the Carolina Breast Cancer Study. We compared unadjusted and adjusted prevalence of cancer-related job or income loss, and a composite measure of either outcome, by rural residence and stratified by race. We included 2435 women: 11.7% were rural; 48.5% were black; and 38.0% reported employment changes after diagnosis. Rural women more often reported employment effects, including reduced household income (43.6% vs 35.4%, two-sided χ2 test P = .04). Rural white, rural black, and urban black women each more often reported income reduction (statistically significant vs. urban white women), although these groups did not meaningfully differ from each other. In multivariable regression, rural differences were mediated by socioeconomic factors, but racial differences remained. Programs and policies to reduce financial toxicity in vulnerable patients should address indirect costs of cancer, including lost wages and employment.
Biological Analysis of SRSF2 Mutations in Leukemogenesis
Authors: Manabu Matsunawa, Masashi Sanada, Ryo Yamamoto, Kenichi Yoshida, Yasunobu Nagata, Ayana Kon, Tetsuichi Yoshizato, Makoto Otsu, Hiromitsu Nakauchi, Seishi Ogawa
Journal: Blood (2012)
Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia
Authors: Jinghui Zhang, Kelly McCastlain, Chunxu Qu, Gang Wu, Michael Edmonson, Yongjin Li, Lei Wei, Debbie Payne-Turner, Hiroki Yoshihara, Michelle L. Churchman, Esmé Waanders, Panagiotis Ntziachristos, Iannis Aifantis, Kathryn G. Roberts, Jing Ma, Guangchun Song, John Easton, Heather L. Mulder, Xiang Chen, Michael Rusch, Kristy Boggs, Bhavin Vadodaria, James Dalton, Marcus L Valentine, Li Ding, Charles Lu, Robert S. Fulton, Lucinda Fulton, Yashodan Tabib, Kerri Ochoa, Meenakshi Devidas, Deqing Pei, Cheng Cheng, William E. Evans, Ching-Hon Pui, Sima Jeha, Richard C. Harvey, I-Ming L Chen, Cheryl L. Willman, Guido Marcucci, Clara D. Bloomfield, Jessica Kohlschmidt, Krzysztof Mrozek, Elisabeth Paietta, Martin S. Tallman, Wendy Stock, Peter M. Voorhees, Janis Racevskis, Jacob M. Rowe, Selina Luger, Steven M. Kornblau, Sheila A Shurtleff, Susana C. Raimondi, Elaine R Mardis, Richard K Wilson, Stephen P Hunger, Mignon L. Loh, James R. Downing, Charles G. Mullighan
Journal: Blood (2015)
Novel Treatment for Therapy-Resistant Mantle Cell Lymphoma Targeting NF-κB and mTOR Signaling Pathways in Vitro and in Vivo
Authors: Nagendra K Chaturvedi, Rajkumar Rajule, Shukla Ashima, Prakash Radhakrishnan, Amarnath Natarajan, Julie M Vose, Shantaram S Joshi
Journal: Blood (2012)
Hepatitis B Virus (HBV) Screening in Hematology/Oncology Patients Who Receive Rituximab: Continued Need for Evidence-Based Standardized Recommendations and Effective Implementation Into Clinical Practice
Authors: Jayde Bednarik, Karen Smethers, Delila Katz, Jennifer S Daly, Roy Guharoy, Alan G. Rosmarin, Andrew M. Evens
Journal: Blood (2012)
Patient Reported Experience Measures in navigated Transcranial Magnetic Stimulation
Authors: Sabina Patel, José Lavrador, Prajwal Ghimire, Richard Gullan, Keyoumars Ashkan, Ranjeev Bhangoo, Francesco Vergani
Journal: Neuro-Oncology (2019)

Abstract Introduction Navigated Transcranial Magnetic Stimulation (nTMS) is a non-invasive adjunct used in surgical planning for lesions in eloquent brain. However, its patient tolerability and effect on their overall healthcare experience is still unknown. To our knowledge, there is no other literature available evaluating patient experience with nTMS. Methods A single-institution prospective cohort study carried out between February 2018 and December 2018 at King’s College Hospital. All patients were supplied with a PREMs-TMS questionnaire to evaluate the different domains of the nTMS experience. Results Feedback was obtained from 50 patients. 26% of patients underwent motor mapping (MM), whilst 74% underwent both motor and language mapping (MLM). The former group reported a better overall experience (p=0.020). The mean exam duration was 103.3±5.1 min (MM 85.8±6.1 min; MLM 106.9±5.9 min). The whole experience of nTMS received positive feedback (94%), particularly with confidence in the staff (95%). Unsurprisingly, the exam domain received a poorer rating (70% as good) with significant anxiety and pain reported in 26% and 24% of patients respectively. None of the studied variables influenced the way patients rated the overall experience of nTMS (p&gt;0.05). Conclusions nTMS is a non-invasive investigative tool, which allows patients to better understand their condition and symptoms related to their lesion. Serial assessment and feedback using a PREM tool, can only improve and enhance this experience. Departmental collaboration may be useful in comparing patient experience with nTMS in different centres.
The Autoantibody Response to ALK In Pediatric Anaplastic Large Cell Lymphoma: A Children's Oncology Group Report
Authors: Megan S. Lim, Karen Pulford, Kamel Ait-Tahar, Suketu D. Patel, Marsha C. Kinney, Sherrie L. Perkins, James R. Anderson, Lynette Smith, Mitchell S. Cairo, Sheila Weitzman, Thomas G. Gross, Jacqueline M. Kraveka
Journal: Blood (2010)
Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category
Authors: Eli Muchtar, Angela Dispenzieri, Shaji Kumar, Rhett P. Ketterling, David Dingli, Martha Q. Lacy, Francis K Buadi, Suzanne R. Hayman, Prashant Kapoor, Nelson Leung, Rajshekhar Chakraborty, Wilson I Gonsalves, Rahma Warsame, Stephen J. Russell, John A Lust, Yi Lin, Ronald S. Go, Steven R. Zeldenrust, Robert A. Kyle, S. Vincent Rajkumar, Morie A. Gertz
Journal: Blood (2016)
The Earliest Activation Marker CD69 Is An Independent and Strong Progression Indicator in B-Cell Chronic Lymphocytic Leukemia.
Authors: Giovanni Del Poeta, Maria Ilaria Del Principe, Cristina Simotti, Francesco Buccisano, Luca Maurillo, Antonella Zucchetto, Licia Ottaviani, Pietro Bulian, Chiara Sarlo, Maria Irno Consalvo, Adriano Venditti, Paolo de Fabritiis, Valter Gattei, Sergio Amadori
Journal: Blood (2009)
Distribution of Genetic and Molecular Prognostic Markers in Young Patients with Chronic Lymphocytic Leukemia (CLL) in Different Phases of the Disease.
Authors: Ilaria Del Giudice, Francesca Romana Mauro, Mauro Nanni, Rita Barzotti, Maria Stefania De Propris, Sara Raponi, Simona Santangelo, Marilisa Marinelli, Nadia Peragine, Daniele Armiento, Francesca Paoloni, Anna Guarini, Robin Foà
Journal: Blood (2009)
CMV Reactivation is Associated with Reduced Relapse Risk, Better Disease-Free Survival and Expansion of Adaptive NK Cells after Reduced Intensity Hematopoietic Cell Transplantation
Authors: Frank Cichocki, Zachary B. Davis, Todd E. DeFor, Sarah A. Cooley, Yenan T. Bryceson, Don J. Diamond, Bruce R. Blazar, Claudio Brunstein, John E. Wagner, Michael R. Verneris, Daniel J. Weisdorf, Jeffrey S. Miller
Journal: Blood (2014)
Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis.
Authors: Marta Coscia, Francesca Pantaleoni, Chiara Riganti, Micol Rigoni, Candida Vitale, Silvia Peola, Daniela Drandi, Marco Ladetto, Amalia Bosia, Mario Boccadoro, Massimo Massaia
Journal: Blood (2009)
FDG-PET SUV Correlates with Expression of Genes Reflecting Proliferation, Metabolism, and Oncogene Activity in Mantle Cell Lymphoma (MCL),
Authors: Mark Roschewski, Marc A. Weniger, Delong Liu, Maria Lindenberg, Stefania Pittaluga, Karen Kurdziel, Kieron Dunleavy, Wyndham H. Wilson, Adrian Wiestner
Journal: Blood (2011)
Involvement of the NOTCH1 and NOTCH2 Genes in B-Cell Lymphomagenesis.
Authors: Iwona Wlodarska, Kim De Keersmaecker, Jan Cools, Chris De Wolf-Peeters, Andre Bosly, Monique Delos, Lucienne Michaux, Peter Vandenberghe, Anne Hagemeijer, Peter Marynen
Journal: Blood (2006)
Association of Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes. Final Results of a Randomized Phase II Multicenter Study
Authors: Carlo Finelli, Cristina Clissa, Matilde Follo, Marta Stanzani, Sarah Parisi, Sara Mongiorgi, Paolo Avanzini, Costanza Bosi, Barbara Castagnari, Anna Candoni, Monica Crugnola, Maria Benedetta Giannini, Marco Gobbi, Giovanna Leonardi, Gian Matteo Rigolin, Domenico Russo, Patrizia Tosi, Giuseppe Visani, Lucio Cocco, Michele Cavo
Journal: Blood (2015)
Long-Term Prognostic Impact of the Use of Erythropoiesis-Stimulating Agents (ESA) in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib.
Authors: Yesid Alvarado, Hagop Kantarjian, Dushyant Verma, Gloria Mattiuzzi, Ahmed Aribi, Farhad Ravandi, Gautam Borthakur, Jorge Cortes
Journal: Blood (2007)
Immunogenicity and Antileukemic Activity of Dendritic Cells Electroporated with Wilms’ Tumor WT1 mRNA: A Phase I/II Trial in Acute Myeloid Leukemia
Authors: Zwi N. Berneman, Ann Van de Velde, Ann Van Driessche, Nathalie Cools, Barbara Stein, Griet Nijs, Katrien Vermeulen, Katrien Pieters, Wilfried A. Schroyens, Alain P. Gadisseur, Inge Vrelust, I. Jolanda de Vries, David A. Price, Yusuke Oji, Haruo Sugiyama, Viggo F. Van Tendeloo
Journal: Blood (2008)
Post-Transplantation High-Dose Cyclophosphamide (Cy) Is Effective Single Agent GVHD Prophylaxis That Permits Prompt Immune Reconstitution after Myeloablative HLA Matched Related and Unrelated Bone Marrow Transplantation (BMT).
Authors: Luznik Leo, Chen R. Allen, Kaup Michele, Bright C. Emilie, Bolanos-Meade Javier, Thorburn J. Christopher, Kos Ferdynand, Hess D. Allan, Jones J. Richard, Fuchs J. Ephraim
Journal: Blood (2006)
Prognostic Impact of the Number of Methylated Genes in Myelodysplastic Syndromes and Acute Myeloid Leukemias Treated with 5-Azacytidine
Authors: María Abáigar, Fernando Ramos, Rocío Benito, María Díez-Campelo, Javier Sánchez-del-Real, Lourdes Hermosin, Juan N Rodríguez, Carlos Aguilar, Isabel Recio, Jose M Alonso, Natalia de-las-Heras, Marta Megido, Marta Fuertes, Consuelo Cañizo, Jesús M Hernández, Jesús F San Miguel
Journal: Blood (2012)
High Mir-221 Expression Is Associated with Poorer Treatment Outcome of Patients with T-Cell Acute Lymphoblastic Leukemia
Authors: Hamilton L. Gimenes-Teixeira, Guilherme A. dos Santos, Dalila L. Zanette, Priscila S Scheucher, Luciana Correa Oliveira de Oliveira, Helder H Paiva, Antonio R Lucena-Araujo, Leandro F. Dalmazzo, Amélia G Araújo, Wilson Silva-Junior, Roberto P. Falcao, Eduardo M. Rego
Journal: Blood (2011)
Fludarabine/Treosulfan/Thiotepa/ATG Conditioning for Matched and Single Antigen Mismatched Unrelated Bone Marrow Transplantation in Haemoglobinopathies Is Feasible and Leads to Early and Sustanined Engraftment with No Long-Term Toxicity or GvHD
Authors: Farah O'Boyle, Leena Karnik, Anne Bradshaw, Richard M Szydlo, Josu de la Fuente
Journal: Blood (2016)
Expression Profiling of a Hemopoietic Cell Survival Transcriptome Identifies a Functional Prognostic Gene Signature in Normal Karyotype AML.
Authors: Mark Guthridge, Daniel Thomas, Emma F Barry, Kok H Chung, Barbara J McClure, L. Bik To, Greg Goodall, Terry P Speed, Motomi Osato, David Haylock, Susie Nilsson, Richard D'Andrea, Angel Lopez, Jason A Powell
Journal: Blood (2009)
TAL1 Super Enhancer Aberration and Stil-TAL1 Fusion in Pediatric T Cell Acute Lymphoblastic Leukemia
Authors: Shunsuke Kimura, Masafumi Seki, Kenichi Yoshida, Hiroo Ueno, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Hiromichi Suzuki, Keisuke Kataoka, Kentaro Ohki, Motohiro Kato, Katsuyoshi Koh, Ryoji Hanada, Nobutaka Kiyokawa, Masao Kobayashi, Atsushi Manabe, Akira Ohara, Yasuhide Hayashi, Satoru Miyano, Seishi Ogawa, Junko Takita
Journal: Blood (2016)
Genetically-Engineered Endothelial Cells Implanted Into the Omentum of Hemophilia A Dogs Provides Long-Term Circulating FVIII Resulting From Sustained FVIII Expression and Persistent Cell Viability.
Authors: Margareth C Ozelo, Hideto Matsui, Carol A. Hegadorn, Lori Harpell, Sandra Powell, James F Hulvat, Andrew Winterborn, Janine Handforth, Christine Hough, David Lillicrap
Journal: Blood (2009)
Using nanobiopsy of single brain tumour cells to investigate transcriptional reprogramming during standard treatment.
Authors: Marilena Elpidorou, Paolo Actis, Lucy Stead
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM) is an incurable brain cancer because, despite aggressive standard treatment (consisting of surgery, radiation and Temozolomide chemotherapy), 100% of tumours recur. GBM tumours are characterised by significant intratumour heterogeneity, with genotypically or phenotypically distinct subpopulations of cells co-existing within each tumour. However, it is not yet known whether the inevitable recurrence of GBM is owing to Darwinian selection of inherently treatment resistant cells within the primary tumour, or the ability of cells to transcriptional reprogram and acquire treatment resistance properties. Knowing this is fundamental to developing more effective treatment for GBM: should we therapeutically target existing cells or their ability to reprogram? The only way to know this is to profile individual cells longitudinally, which has not been possible until now. Here we present a pioneering technology, known as nanobiopsy, which can longitudinally track the transcriptional profile of single GBM cells through standard treatment. The nanobiopsy allows injection or extraction of cytoplasmic material by electrowetting. We have proved that this technique is able to sample cytoplasmic fractions from cells without killing them, giving us the advantage to capture the transcriptional changes occurring through treatment using optimised scRNA sequencing protocols. We are applying this novel technology to help us identify treatment resistance modes and mechanisms to reveal novel targets for drug development.
Early Diagnostic Procedure and Treatment for Invasive Fungal Infection Centered on Invasive Aspergillosis in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia
Authors: Kouhei Kyo, Takeshi Okatani, Ryota Imanaka, Mitsuhiro Itagaki, Yuuta Katayama, Taiichi Kyo
Journal: Blood (2011)
Negative Feedback Signaling Enables Leukemic Transformation by Oncogenic Tyrosine Kinases
Authors: Seyedmehdi Shojaee, Maike Buchner, Srividya Swaminathan, Huimin Geng, Linda Chan, Marle Bothe, Zhengshan Chen, Ari Melnick, Jeffery Molkentin, Gail Martin, H. Phillip Koeffler, Markus Muschen
Journal: Blood (2012)
High Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule(CEACAM) 6 In Primary Myelofibrosis
Authors: Hans Carl Hasselbalch, Vibe Skov, Thomas Stauffer Larsen, Mads Thomassen, Caroline Riley, Morten Krogh Jensen, Ole Weis Bjerrum, Torben A Kruse
Journal: Blood (2010)
RNA Interference Screen Implicates TNFAIP3 and FOXO1 in MALT1 Inhibition Resistance
Authors: Lorena Fontan, Rebecca Goldstein, Gabriella Casalena, Himaly Shinglot, Ilkay Us, Haiying Ju, Yanwen Jiang, Natalia Bilchuk, Ari Melnick
Journal: Blood (2016)
Outcome of Frontline Treatment with Generic Imatinib in Adult Patients with Chronic Myeloid Leukemia in Algerian Population: A First Multicenter Study
Authors: Badra Entasoltan, Mohamed Amine Bekadja, Rachid Amar Bouhass, Karima Taibi, Hadj Touhami, Nemra Mehalhal, Mohamed Benlazar, Zahia Zouaoui, Brahim Benzineb, Naima Mesli, Mustapha Talbi, Toufik Yachekour, Aissa Bachiri, Mourad Nachi
Journal: Blood (2016)
The Oncogenic Role of Tumor Suppressor Protein p27 in Ph+ Chronic Myeloid Leukemia.
Authors: Anupriya Agarwal, Ryan Mackenzie, Dorian LaTocha, Kavin Vasudevan, Eduardo Firpo, Marc Loriaux, Keiichi Nakayama, Brian J. Druker, James M Roberts, Michael Deininger
Journal: Blood (2009)
Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma
Authors: Lola-Jade Palmieri, Solène Dermine, Romain Coriat
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Overcoming Drug Resistance of Pre-B ALL Cells By Targeting Integrin alpha6 Associated Cell-Adhesion Mediated Drug Resistance Using a Novel Antibody, P5G10
Authors: EunJi Gang, Yao-Te Hsieh, Hye Na Kim, Yann Duchartre, Shishido Stephanie, Markus Muschen, Elizabeth Wayner, Nora Heisterkamp, Halvard Bonig, Yong-Mi Kim
Journal: Blood (2015)
External Validation On Biological Basis of New Prognostic Index in Early Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients: The Gruppo Italiano Studio Linfomi (GISL) Experience.
Authors: Stefano Molica, Sonia Fabris, Giovanna Cutrona, Massimo Gentile, Emanuela Anna Pesce, Francesco Di Raimondo, Caterina Musolino, Marco Gobbi, Nicola Di Renzo, Francesca Mauro, Renato Cantaffa, Maura Brugiatelli, Francesco Merli, Simonetta Zupo, Caterina Mammi, Luca Baldini, Francesco Angrilli, Gianni Quintana, Ugo Consoli, Giovanni Bertoldero, Emilio Iannitto, Paolo Di Tonno, Antonio Fragasso, Pellegrino Musto, Maria Cristina Cox, Gianluca Festini, Vincenzo Callea, Stefano Sacchi, Agostino Cortelezzi, Giorgio Lambertenghi, Robert Foà, Antonino Neri, Massimo Federico, Manlio Ferrarini, Fortunato Morabito
Journal: Blood (2009)
Phloridzin Docosahexaenoate (PZ-DHA) : A Novel Naturally Derived Drug Active in T-Cell Acute Lymphoblastic Leukemia (T-ALL)
Authors: Niroshaathevi Arumuggam, Nicole Melong, Catherine K.L. Too, Jason N. Berman, H.P. Vasantha Rupasinghe
Journal: Blood (2016)
Identifying Sepsis Phenotypes—Reply
Authors: Christopher W. Seymour, Derek C. Angus
Journal: JAMA (2019)

In Reply We agree with Dr Moser and colleagues that heterogeneity in sepsis is an important area of study. Many of the differences in patients with sepsis are clinically apparent, and yet unsupervised methods may identify emerging patterns or phenotypes not otherwise discernible at the bedside.
Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.
Authors: David Siegel, Sundar Jagannath, Sagar Lonial, Meletios A. Dimopoulos, Thorsten Graef, Dina Pietrangelo, Lisa Lupinacci, David Reiser, Syed Rizvi, Kenneth C. Anderson
Journal: Blood (2009)
Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with FLT3-ITD AML
Authors: Yi-Bin Chen, Li Shuli, Lane A. Andrew, Christine Connolly, Candice Del Rio, Betsy Valles, Morgan Curtis, Karen K. Ballen, Corey S Cutler, Bimalangshu R Dey, Areej El-Jawahri, Amir T. Fathi, Vincent T Ho, Amy Joyce, Steven L. McAfee, Michelle A Rudek, Trivikram Rajkhowa, Sigitas Verselis, Joseph H. Antin, Thomas R. Spitzer, Mark Levis, Robert J. Soiffer
Journal: Blood (2014)
A Longitudinal Prospective Study Evaluating the Effects of Eltrombopag Treatment On Bone Marrow in Patients with Chronic Immune Thrombocytopenia: Interim Analysis At 1 Year.
Authors: Russell K. Brynes, Attilio Orazi, Raymond S.M. Wong, Kalpana Bakshi, Christine K Bailey, Andres Brainsky
Journal: Blood (2012)
Immune Reconstitution and Clinical Outcome After Donor Lymphocyte Infusion for Relapsed Disease After Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Diseases Other Than Chronic Myelogenous Leukemia.
Authors: Daniela S. Krause, Julie Aldridge, Haesook T Kim, Sean McDonough, Laura Gatzos, Joseph H. Antin, Vincent Ho, Corey Cutler, Philippe Armand, John Koreth, Robert J Soiffer, Jerome Ritz, Grace S Kao
Journal: Blood (2009)
Pharmacological IRS1/2 Inhibition Induces Apoptosis in BCR-ABL1T315I mutant Cells
Authors: Renata Scopim-Ribeiro, João Agostinho Machado-Neto, Christopher A. Eide, Paula de Melo Campos, Priscila Santos Scheucher, Sara Teresinha Olalla Saad, Eduardo Magalhães Rego, Cristina E. Tognon, Brian J. Druker, Fabiola Traina
Journal: Blood (2016)
Association in Outcome of Advanced Multiple Myeloma with Polymorphisms of Inflammatory-Related Genes IL-1A, IL-1B, IL1RN, TNF-a and TNFRSF1B.
Authors: Gabriele Buda, Alessandro Martino, Enrico Orciuolo, Antonella Lupia, Sara Galimberti, Massimo Gentile, Marino Brunori, Fortunato Morabito, Anna Maria Rossi, Mario Petrini
Journal: Blood (2009)
Outcome of Acute Myeloid Leukemia Patients with Hyperleukocytosis in Brazil.
Authors: Luciana Correa Oliveira de Oliveira, Lucas Gabriel Maltoni Romano, Benedito Pina Almeida Prado Junior, Dimas Tadeu Covas, Eduardo Magalhaes Rego, Gil Cunha De Santis
Journal: Blood (2009)
Absolute Lymphocyte Count and CD4 Count Predict a Superior Progression-Free Survival in Non-Hodgkin Lymphoma Patients Treated with Rituximab and Interleukin-12.
Authors: Cristina Joao, Luis F. Porrata, Thomas Witzig, Paul Kurtin, Ivana Micallef, Svetomir N. Markovic, Charles Erlichman, Anne Novak, Stephen M. Ansell
Journal: Blood (2005)
Impact of Radiotherapy and Rituximab on Outcome of Stage I(E) Diffuse Large B-Cell Lymphoma
Authors: Marcel Nijland, Karin Boslooper, Anke Van den Berg, Hanneke C. Kluin-Nelemans, Peter Joosten, Huib Storm, Robby Kibbelaar, Gustaaf van Imhoff, Mels Hoogendoorn
Journal: Blood (2015)
Semi-Solid Decalcification and Research System: a Novel Method to Study Fluorescence Protein Gene Modified Stem Cells In Bone.
Authors: Qian-li Jiang, Shan Jiang, Fei-li Chen, Li-qiong Zhu, Pei-ran Zhao, Hao-jia Huang, Xiao-hong He, Chang-xin Yin, Fan Yi Meng
Journal: Blood (2010)
Personalized Daily Doses of Imatinib By Therapeutic Drug Monitoring Increase the Rates of Molecular Responses in Patients with Chronic Myeloid Leukemia. Final Results of the Randomized OPTIM Imatinib Study
Authors: Philippe Rousselot, Hyacinthe Johnson-Ansah, Françoise Huguet, Laurence Legros, Martine Escoffre-Barbe, Martine Gardembas, Pascale Cony-Makhoul, Valérie Coiteux, Laurent Sutton, Wajed Abarah, Camille Pouaty, Jean Michel Pignon, Bachra Choufi, Sorin Visanica, Bénédicte Deau, Stephane Bouchet, Francois Guilhot, Francois-Xavier Mahon, Laure Morisset, Jean-Michel Cayuela, Benjamin Maneglier
Journal: Blood (2015)
Exome Sequencing Identifies Genes and Variant Alleles Associated With Severity Of Iron Overload In Hemochromatosis HFE C282Y Homozygotes
Authors: Christine E. McLaren, Mary J. Emond, Pradyumna D. Phatak, Paul C. Adams, V. Nathan Subramaniam, James C. Barton, Lawrie W. Powell, Lyle C. Gurrin, Katrina J. Allen, Deborah A. Nickerson, Tin Louie, Grant A. Ramm, Gregory J. Anderson, Gordon D. McLaren
Journal: Blood (2013)